Developer docs
API playgroundTry for free, no card

Search company profiles

HBM Partners

Full company profile

uuid00085ai

Namestring
HBM Partners
Legal namestring
HBM Partners AG
Websiteurl
hbmpartners.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

HBM Partners AG is a Swiss-domiciled, FINMA-regulated asset manager founded in 2001 and headquartered in Zug, Switzerland. The firm specializes in healthcare investments, focusing on venture, growth, and buy-out financings of private companies as well as public company investments across biopharma, medtech, diagnostics, and healthcare services. Geographic coverage spans Europe, North America, India, China, and other emerging markets, with typical ticket sizes of USD 5–50 million per transaction.

The firm operates six distinct investment vehicles: the SIX-listed HBM Healthcare Investments AG (the flagship public equity vehicle), two Luxembourg-domiciled UCITS open-ended funds (HBM Global Biotechnology Fund and HBM Global Healthcare Fund), and three Cayman-based private funds (HBM Panorama Healthcare Fund, HBM Cobra India, and HBM China Healthcare Fund). HBM serves as investment manager or advisor to these vehicles, with FundPartner Solutions (Pictet Group) acting as UCITS representative and administrator, and First Independent Fund Services and NPB New Private Bank serving Cayman fund operations. The firm also maintains a Hong Kong subsidiary to support Asian deal sourcing and portfolio company oversight.

HBM Partners generates revenue exclusively through recurring management fees (for collective investment scheme management) and advisory fees (for sub-advised vehicles), billed annually. The firm does not charge distribution commissions and serves only institutional and professional clients. With USD 2.1 billion in assets under management and a team of 11–50 professionals, HBM has executed over 100 investments resulting in more than 60 trade sales and IPOs. The senior team includes CEO Dr. Andreas Wicki (30+ years healthcare investing), CFO Erwin Troxler, and investment heads with Lombard Odier and Bank Sarasin pedigrees.

Short descriptiontext

HBM Partners is a FINMA-regulated Swiss healthcare asset manager founded in 2001, managing USD 2.1 billion AUM across private and public investments in biopharma, medtech, diagnostics, and healthcare for institutional investors globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersZug, Switzerland
HQ citystring
Zug
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare asset management, private equity investments, biopharma venture capital, growth equity financing, healthcare investment funds
Industry1 code
PRIMARYFSANAAAJ
Venture Capital Fund-of-Funds / Multi-Manager Platforms
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Asset Management
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees
TypeSubscription Recurring
Description

HBM receives compensation as portfolio manager with a Management Fee for its services in managing collective investment schemes. This represents HBM's sole compensation for services to the Financial Instruments and to the client.

hbmpartners.com
2Advisory Fees
TypeSubscription Recurring
Description

HBM acts as investment advisor to certain funds (such as HBM Cobra India Fund) pursuant to an investment advisory agreement and receives Advisory Fees for providing advice, analysis of the selection of investments, and preparing periodic reports.

hbmpartners.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D
Pricing details1 tier
1Management Fee / Advisory Fee model
ModelSubscriptionBilling cadenceAnnual
Notes

HBM is compensated as portfolio manager with a Management Fee or as advisor with an Advisory Fee. These fees represent HBM's sole compensation for all services. No separate distribution commissions are charged to clients.

hbmpartners.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

HBM Partners is a Swiss healthcare-focused asset manager that invests in venture, growth, and buy-out financings of private companies as well as public companies in the biopharma, medtech, diagnostics, and healthcare sectors. The firm manages USD 2.1 billion in assets under management and advises six investment vehicles, including the SIX-listed HBM Healthcare Investments Ltd, two UCITS funds, and three Cayman-based private funds.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 100 investments completed with more than 60 trade sales and IPOs
+1 more record
Product overview1 text field

HBM Partners is a Swiss healthcare-focused asset manager that provides investment management and advisory services to healthcare companies across Europe, North America, and Emerging Markets. The firm advises several specialized public and private equity investment vehicles including the SIX-listed HBM Healthcare Investments Ltd, two Luxembourg-domiciled UCITS funds (HBM Global Biotechnology Fund and HBM Global Healthcare Fund), and three Cayman-based private funds (HBM Panorama Healthcare Fund, HBM Cobra India, and HBM China Healthcare Fund). Founded in 2001 and regulated by FINMA, HBM Partners manages USD 2.1 billion in assets under management, focusing on venture, growth and buy-out financings of private companies as well as investments in public companies in biopharma, medtech, diagnostics and healthcare sectors. Investment sizes typically range from USD 5 to 50 million.

Product and service6 records
1HBM Healthcare Investments
CategoryPublic Equity Investment Vehicle Public Equity Investment Vehicle Public Equity Investment Vehicle
Description

SIX-listed investment company that is the primary public equity vehicle advised by HBM Partners, focusing on healthcare investments across biopharma, medtech, diagnostics and healthcare services.

2HBM Global Biotechnology Fund
CategoryOpen-ended Investment Fund (UCITS) Open-ended Investment Fund (UCITS) Open-ended Investment Fund (UCITS)
Description

Open-ended investment fund with multiple compartments governed by Luxembourg law, established in accordance with UCITS provisions. HBM serves as investment advisor with FundPartner Solutions as representative and Banque Pictet & Cie SA as paying agent.

3HBM Global Healthcare Fund
CategoryOpen-ended Investment Fund (UCITS) Open-ended Investment Fund (UCITS) Open-ended Investment Fund (UCITS)
Description

Open-ended investment fund with multiple compartments governed by Luxembourg law, established in accordance with UCITS provisions. Part of the same UCITS structure as the HBM Global Biotechnology Fund.

4HBM Panorama Healthcare Fund
CategoryPrivate Fund (Cayman) Private Fund (Cayman) Private Fund (Cayman)
Description

Cayman-based private healthcare fund with First Independent Fund Services as representative and NPB New Private Bank as paying agent. HBM acts as investment manager.

5HBM Cobra India
CategoryPrivate Fund (Cayman) Private Fund (Cayman) Private Fund (Cayman)
Description

Cayman-based private fund focused on Indian healthcare investments. HBM acts as investment advisor pursuant to an investment advisory agreement, with First Independent Fund Services as representative and NPB New Private Bank as paying agent.

6HBM China Healthcare Fund
CategoryPrivate Fund (Cayman) Private Fund (Cayman) Private Fund (Cayman)
Description

Cayman-based private fund focused on Chinese healthcare investments. HBM acts as investment manager based on dedicated investment management agreements, with First Independent Fund Services as representative and NPB New Private Bank as paying agent.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1FundPartner Solutions (Suisse) SA (Pictet Group)
Strategic tierCoreTypeTechnology or Integration
Description

FundPartner Solutions acts as representative and administrator for the UCITS funds (HBM Global Biotechnology Fund and HBM Global Healthcare Fund). The firm is part of the Pictet Group and provides investment management services, administrative agency, corporate and domiciliary agency, paying agent, registrar and transfer agency services to the UCITS.

hbmpartners.com
2Banque Pictet & Cie SA
Strategic tierCoreTypeOthers
Description

Appointed as paying agent for the HBM Global Biotechnology Fund and HBM Global Healthcare Fund UCITS vehicles.

hbmpartners.com
Strategic tierCoreTypeOthers
Description

Appointed as representative for the Cayman-based funds: HBM Panorama Healthcare Fund, HBM Cobra India and HBM China Healthcare Fund.

Strategic tierCoreTypeOthers
Description

Appointed as paying agent for the Cayman-based HBM Panorama Healthcare Fund, HBM Cobra India and HBM China Healthcare Fund.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

SIX-listed stock corporation. HBM Partners advises this entity. There is some overlap in personnel between HBM and HBI, although it is contractually ensured that employees concerned are independent of instructions. HBM distributes shares of HBM Healthcare Investment AG to qualified investors.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the largest healthcare-dedicated investment firms globally, investing across venture, growth, public equity, and royalty/structured finance in biopharma, medtech, and diagnostics. Direct peer to HBM Partners given nearly identical strategy, sector specialization, and stage focus.

2Baker Bros. Advisors
TypeDirect peer
Description

Long-only healthcare-focused investment firm investing in biotech equities across public and private markets. Closely comparable to HBM's public-private healthcare crossover approach.

TypeDirect peer
Description

Munich-based European life sciences venture capital firm investing across biopharma, medtech, and diagnostics. Co-investor with HBM on companies such as Adrenomed and Sphingotec, making it a directly comparable European healthcare specialist.

TypeDirect peer
Description

Paris-based European healthcare and life sciences venture capital firm investing across biopharma, medtech, and digital health. Direct peer given overlapping stage focus, sector specialization, and European base with global reach similar to HBM.

TypeDirect peer
Description

European healthcare-dedicated venture and growth capital firm with multiple fund vintages across biopharma and medtech. Highly comparable to HBM in stage focus, sector specialization, and European base of operations.

TypeDirect peer
Description

Boston-based healthcare-focused investment manager spanning public and private biotech equities and venture. Directly comparable to HBM in combining public and private healthcare exposure under one platform.

TypeBroad incumbent
Description

Holding company of the Novo Nordisk Foundation, investing broadly in life sciences venture and growth equity globally. Comparable to HBM in healthcare focus and stage coverage, but with substantially larger AUM and permanent capital base.

TypeDirect peer
Description

Early-stage life sciences venture firm building biotech companies from inception. Comparable to HBM on the venture side of its platform with similar scientific rigor and biotech focus, though Atlas is more stage-narrow.

TypeBroad incumbent
Description

Multi-stage venture and growth firm with a dedicated healthcare practice spanning therapeutics, medtech, and digital health. Broader incumbent peer given diversified sector exposure alongside HBM-comparable healthcare activity.

TypeEmerging player
Description

European healthcare-dedicated growth fund focused on later-stage biopharma companies. Comparable to HBM's growth-stage healthcare mandate and emerging as a relevant European peer in the same niche.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment57 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HBM Partners

Healthcare Asset Managementhbmpartners.com

HBM Partners is a FINMA-regulated Swiss healthcare asset manager founded in 2001, managing USD 2.1 billion AUM across private and public investments in biopharma, medtech, diagnostics, and healthcare for institutional investors globally.

What HBM Partners does

HBM Partners AG is a Swiss-domiciled, FINMA-regulated asset manager founded in 2001 and headquartered in Zug, Switzerland. The firm specializes in healthcare investments, focusing on venture, growth, and buy-out financings of private companies as well as public company investments across biopharma, medtech, diagnostics, and healthcare services. Geographic coverage spans Europe, North America, India, China, and other emerging markets, with typical ticket sizes of USD 5–50 million per transaction.

The firm operates six distinct investment vehicles: the SIX-listed HBM Healthcare Investments AG (the flagship public equity vehicle), two Luxembourg-domiciled UCITS open-ended funds (HBM Global Biotechnology Fund and HBM Global Healthcare Fund), and three Cayman-based private funds (HBM Panorama Healthcare Fund, HBM Cobra India, and HBM China Healthcare Fund). HBM serves as investment manager or advisor to these vehicles, with FundPartner Solutions (Pictet Group) acting as UCITS representative and administrator, and First Independent Fund Services and NPB New Private Bank serving Cayman fund operations. The firm also maintains a Hong Kong subsidiary to support Asian deal sourcing and portfolio company oversight.

HBM Partners generates revenue exclusively through recurring management fees (for collective investment scheme management) and advisory fees (for sub-advised vehicles), billed annually. The firm does not charge distribution commissions and serves only institutional and professional clients. With USD 2.1 billion in assets under management and a team of 11–50 professionals, HBM has executed over 100 investments resulting in more than 60 trade sales and IPOs. The senior team includes CEO Dr. Andreas Wicki (30+ years healthcare investing), CFO Erwin Troxler, and investment heads with Lombard Odier and Bank Sarasin pedigrees.

HBM Partners firmographics

Firmographics
Name
HBM Partners
Legal name
HBM Partners AG
Website
https://hbmpartners.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
11–50 employees
Short description
HBM Partners is a FINMA-regulated Swiss healthcare asset manager founded in 2001, managing USD 2.1 billion AUM across private and public investments in biopharma, medtech, diagnostics, and healthcare for institutional investors globally.
Ownership category
akta.pro rank

HBM Partners industry classification

Industry
Product category
Healthcare Asset Management
NAICS
Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAJ
Venture Capital Fund-of-Funds / Multi-Manager Platforms

Keywords

  • Healthcare asset management
  • Private equity investments
  • Biopharma venture capital
  • Growth equity financing
  • Healthcare investment funds

Where HBM Partners is headquartered

Location

Headquarters

HQ city
Zug
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

HBM Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

  1. Management Fees: HBM receives compensation as portfolio manager with a Management Fee for its services in managing collective investment schemes. This represents HBM's sole compensation for services to the Financial Instruments and to the client.
  2. Advisory Fees: HBM acts as investment advisor to certain funds (such as HBM Cobra India Fund) pursuant to an investment advisory agreement and receives Advisory Fees for providing advice, analysis of the selection of investments, and preparing periodic reports.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualManagement Fee / Advisory Fee model

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

HBM Partners product offering

Product offering

Core offering

HBM Partners is a Swiss healthcare-focused asset manager that invests in venture, growth, and buy-out financings of private companies as well as public companies in the biopharma, medtech, diagnostics, and healthcare sectors. The firm manages USD 2.1 billion in assets under management and advises six investment vehicles, including the SIX-listed HBM Healthcare Investments Ltd, two UCITS funds, and three Cayman-based private funds.

Product overview

HBM Partners is a Swiss healthcare-focused asset manager that provides investment management and advisory services to healthcare companies across Europe, North America, and Emerging Markets. The firm advises several specialized public and private equity investment vehicles including the SIX-listed HBM Healthcare Investments Ltd, two Luxembourg-domiciled UCITS funds (HBM Global Biotechnology Fund and HBM Global Healthcare Fund), and three Cayman-based private funds (HBM Panorama Healthcare Fund, HBM Cobra India, and HBM China Healthcare Fund). Founded in 2001 and regulated by FINMA, HBM Partners manages USD 2.1 billion in assets under management, focusing on venture, growth and buy-out financings of private companies as well as investments in public companies in biopharma, medtech, diagnostics and healthcare sectors. Investment sizes typically range from USD 5 to 50 million.

Differentiator

Problem solved

Functional benefit

Products and services

  • HBM Healthcare Investments SIX-listed investment company that is the primary public equity vehicle advised by HBM Partners, focusing on healthcare investments across biopharma, medtech, diagnostics and healthcare services.
  • HBM Global Biotechnology Fund Open-ended investment fund with multiple compartments governed by Luxembourg law, established in accordance with UCITS provisions. HBM serves as investment advisor with FundPartner Solutions as representative and Banque Pictet & Cie SA as paying agent.
  • HBM Global Healthcare Fund Open-ended investment fund with multiple compartments governed by Luxembourg law, established in accordance with UCITS provisions. Part of the same UCITS structure as the HBM Global Biotechnology Fund.
  • HBM Panorama Healthcare Fund Cayman-based private healthcare fund with First Independent Fund Services as representative and NPB New Private Bank as paying agent. HBM acts as investment manager.
  • HBM Cobra India Cayman-based private fund focused on Indian healthcare investments. HBM acts as investment advisor pursuant to an investment advisory agreement, with First Independent Fund Services as representative and NPB New Private Bank as paying agent.
  • HBM China Healthcare Fund Cayman-based private fund focused on Chinese healthcare investments. HBM acts as investment manager based on dedicated investment management agreements, with First Independent Fund Services as representative and NPB New Private Bank as paying agent.

Quantifiable outcome

  • Over 100 investments completed with more than 60 trade sales and IPOs
  • +1 more outcomes

Companies that use HBM Partners

Customer profile

Named customers6 records

Segments2 records

Ideal customer profiles1 record

HBM Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

HBM Partners partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and flagship.

  • FundPartner Solutions (Suisse) SA (Pictet Group)coreTechnology or IntegrationFundPartner Solutions acts as representative and administrator for the UCITS funds (HBM Global Biotechnology Fund and HBM Global Healthcare Fund). The firm is part of the Pictet Group and provides investment management services, administrative agency, corporate and domiciliary agency, paying agent, registrar and transfer agency services to the UCITS.
  • Banque Pictet & Cie SAcoreOthersAppointed as paying agent for the HBM Global Biotechnology Fund and HBM Global Healthcare Fund UCITS vehicles.
  • First Independent Fund Services LtdcoreOthersAppointed as representative for the Cayman-based funds: HBM Panorama Healthcare Fund, HBM Cobra India and HBM China Healthcare Fund.
  • NPB New Private Bank LtdcoreOthersAppointed as paying agent for the Cayman-based HBM Panorama Healthcare Fund, HBM Cobra India and HBM China Healthcare Fund.
  • HBM Healthcare Investments AGflagshipStrategic or Co-development PartnerSIX-listed stock corporation. HBM Partners advises this entity. There is some overlap in personnel between HBM and HBI, although it is contractually ensured that employees concerned are independent of instructions. HBM distributes shares of HBM Healthcare Investment AG to qualified investors.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

HBM Partners competitors and assessment

Company assessment

Direct peers

  • Orbimed Advisors: One of the largest healthcare-dedicated investment firms globally, investing across venture, growth, public equity, and royalty/structured finance in biopharma, medtech, and diagnostics. Direct peer to HBM Partners given nearly identical strategy, sector specialization, and stage focus.
  • Baker Bros. Advisors: Long-only healthcare-focused investment firm investing in biotech equities across public and private markets. Closely comparable to HBM's public-private healthcare crossover approach.
  • Wellington Partners: Munich-based European life sciences venture capital firm investing across biopharma, medtech, and diagnostics. Co-investor with HBM on companies such as Adrenomed and Sphingotec, making it a directly comparable European healthcare specialist.
  • Sofinnova Partners: Paris-based European healthcare and life sciences venture capital firm investing across biopharma, medtech, and digital health. Direct peer given overlapping stage focus, sector specialization, and European base with global reach similar to HBM.
  • Forbion: European healthcare-dedicated venture and growth capital firm with multiple fund vintages across biopharma and medtech. Highly comparable to HBM in stage focus, sector specialization, and European base of operations.
  • RA Capital Management: Boston-based healthcare-focused investment manager spanning public and private biotech equities and venture. Directly comparable to HBM in combining public and private healthcare exposure under one platform.
  • Atlas Venture: Early-stage life sciences venture firm building biotech companies from inception. Comparable to HBM on the venture side of its platform with similar scientific rigor and biotech focus, though Atlas is more stage-narrow.

Broad incumbents

  • Novo Holdings (Novo Ventures): Holding company of the Novo Nordisk Foundation, investing broadly in life sciences venture and growth equity globally. Comparable to HBM in healthcare focus and stage coverage, but with substantially larger AUM and permanent capital base.
  • Polaris Partners: Multi-stage venture and growth firm with a dedicated healthcare practice spanning therapeutics, medtech, and digital health. Broader incumbent peer given diversified sector exposure alongside HBM-comparable healthcare activity.

Emerging players

  • Jeito Capital: European healthcare-dedicated growth fund focused on later-stage biopharma companies. Comparable to HBM's growth-stage healthcare mandate and emerging as a relevant European peer in the same niche.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

HBM Partners compliance and trust

Trust signal

Compliance5 records

HBM Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HBM Partners leadership team

Management profile

Number of profiles

Profiles8 records

HBM Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HBM Partners M&A and investment

M&A and investment

M&A

Investments57 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HBM Partners

What does HBM Partners do?

HBM Partners is a Swiss healthcare-focused asset manager that invests in venture, growth, and buy-out financings of private companies as well as public companies in the biopharma, medtech, diagnostics, and healthcare sectors. The firm manages USD 2.1 billion in assets under management and advises six investment vehicles, including the SIX-listed HBM Healthcare Investments Ltd, two UCITS funds, and three Cayman-based private funds.

Is HBM Partners a public or private company?

HBM Partners is a private company. It is classified as unknown and is currently operating.

When was HBM Partners founded?

HBM Partners was founded in 2001. It employs 11 to 50 people.

Where is HBM Partners based?

HBM Partners is headquartered in Zug, Switzerland, in the Europe region.

How does HBM Partners make money?

Two revenue lines are on record. Management Fees are the primary driver. The others are advisory Fees.

Who are HBM Partners's main competitors?

Direct peers on record are Orbimed Advisors, Baker Bros. Advisors, Wellington Partners, Sofinnova Partners, Forbion, RA Capital Management and Atlas Venture. Broad incumbents are Novo Holdings (Novo Ventures) and Polaris Partners. Jeito Capital is listed as an emerging player.

Does HBM Partners have an API?

No public API is recorded for HBM Partners.

What industry is HBM Partners in?

HBM Partners's product category is Healthcare Asset Management. Its primary akta.pro industry code is FSANAAAJ, Venture Capital Fund-of-Funds / Multi-Manager Platforms. Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
UnquoteNovo, HBM lead CHF 100m round for NumabNovo Ventures and HBM Partners led a CHF 100m series-C round for Numab Therapeutics, a Swiss multi-specific antibodies developer. The funding will advance its lead drug candidate NM21-1408 into clinical trials and support its oncology and inflammation pipeline. Existing investors also participated.PitchBookThe top 10 most active VCs in SwitzerlandSwiss VC funding broke €1 billion last year, with 22 companies raising €465 million in Q2 2019. The top 10 most active VCs include Investiere, Novartis Venture Fund, and HBM Partners, with deal counts from 37 to 68.FinSMEssphingotec Raises €20M in Equity Financing - FinSMEsSphingotec, a German diagnostics company, closed a €20M growth equity financing led by HBM and Wellington Partners. The funds will roll out its fully automated IB 10 point-of-care platform for acute blood biomarkers. The company has over 1,000 ICUs and emergency departments using its platform, with more than 100,000 tests annually.LifescivcThe Inescapable Gravity Of Biotech’s Key Clusters: The Great Consolidation Of Talent, Capital, & Returns - LifeSciVCBoston and San Francisco dominate biotech, capturing nearly half of global venture capital and 60-70% of US funding. Startups in these clusters exit 2-3 years faster and at higher valuations than elsewhere. The consolidation of talent and capital shows no signs of abating.LifescivcA Tale of Two Startup Worlds: Biotech And Tech VC Ecosystems - LifeSciVCThe article compares biotech and tech venture capital ecosystems, noting biotech startup creation is flat while tech startup creation is up 3x since 2009-2010. Tech funding is up nearly 5x, while biotech funding is up only 75%, and biotech IPOs have cooled 25% year-over-year. The author argues biotech remains in steady-state balance, while tech faces a startup glut.LifescivcData Snapshot: VC-Backed BioPharma M&A 2014 - LifeSciVCHBM Partners' 2014 report found VC-backed biopharma M&A was the best exit year in a decade, with deal values topping $5B upfront and $8B total. Average deal values rose while capital intensity stayed steady, and return multiples tripled since 2005-2007. The author expects the M&A environment to remain attractive.LifescivcBiotech M&A: Steadily Delivering Returns in 2013 - LifeSciVCIn 2013, 49 private biotech acquisitions generated $18B in proceeds, with an average VC-backed exit of $372M. Upfront payments alone totaled $5.5B, and investors could realize up to $7.3B including earnouts. The author expects returns to rise as IPO distributions come in.LifescivcBiotech M&A in 2012: The Good, Bad, and Ugly - LifeSciVCHBM Partners reported 2012 biotech M&A deal values of $3.5B upfront and $8.5B total for venture-backed deals. Median investor multiples rose to 3.5x, but European exits lagged at 1.3x, and time from founding to trade sale increased to about 9 years.LifescivcFavorable 1H2011 Biotech M&A Trends - LifeSciVCH1 2011 biotech M&A saw 18 deals valued over $200M, with upfront transaction values reaching $51.6B. VC/PE-backed deal volume hit a record $17.2B, driven by Takeda's $13.7B acquisition of Nycomed. Venture-backed exits returned 2.7x invested capital, up from 1.6x in 2010.Lifescivc2010 M&A Analytics: Some Observations - LifeSciVCHBM Partners' 2010 biotech M&A survey shows acquisitions of VC-backed biotech firms rose over twice as much as in 2008, reaching 2007 levels. Average upfronts in earnout deals fell to 1.5-2x, with 3-4x total, and small/mid-cap public firms now drive 60% of volume.